Improving Lung Function in Patients With SSc-ILD

Richard M. Silver, MD


March 24, 2021

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is one of the most common manifestations of systemic sclerosis (scleroderma) and the most common cause of death in patients with this disease.

All scleroderma patients should be evaluated for ILD and treated appropriately. Currently, immunosuppressive therapies, including mycophenolate mofetil and cyclophosphamide, are the mainstay treatment for progressive SSc-ILD. Studies have shown promising results with antifibrotic therapies such as nintedanib and pirfenidone.

Dr Richard Silver, of the Medical University of South Carolina, discusses how current therapies, including new antifibrotic medications, can be used to improve lung function in patients with SSc-ILD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.